Biological activity of tumor-treating fields in preclinical glioma models
Open Access
- 20 April 2017
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cell Death & Disease
- Vol. 8 (4), e2753
- https://doi.org/10.1038/cddis.2017.171
Abstract
Glioblastoma is the most common and aggressive form of intrinsic brain tumor with a very poor prognosis. Thus, novel therapeutic approaches are urgently needed. Tumor-treating fields (TTFields) may represent such a novel treatment option. The aim of this study was to investigate the effects of TTFields on glioma cells, as well as the functional characterization of the underlying mechanisms. Here, we assessed the anti-glioma activity of TTFields in several preclinical models. Applying TTFields resulted in the induction of cell death in a frequency- and intensity-dependent manner in long-term glioma cell lines, as well as glioma-initiating cells. Cell death occurred in the absence of caspase activation, but involved autophagy and necroptosis. Severe alterations in cell cycle progression and aberrant mitotic features, such as poly- and micronucleation, preceded the induction of cell death. Furthermore, exposure to TTFields led to reduced migration and invasion, which are both biological hallmarks of glioma cells. The combination of TTFields with irradiation or the alkylating agent, temozolomide (TMZ), resulted in additive or synergistic effects, and the O6-methyl-guanine DNA methyltransferase status did not influence the efficacy of TTFields. Importantly, TMZ-resistant glioma cells were responsive to TTFields application, highlighting the clinical potential of this therapeutic approach. In summary, our results indicate that TTFields induce autophagy, as well as necroptosis and hamper the migration and invasiveness of glioma cells. These findings may allow for a more detailed clinical evaluation of TTFields beyond the clinical data available so far.Keywords
This publication has 32 references indexed in Scilit:
- Tumor treating fields inhibit glioblastoma cell migration, invasion and angiogenesisOncotarget, 2016
- GliomaNature Reviews Disease Primers, 2015
- MicroRNA-mediated down-regulation of NKG2D ligands contributes to glioma immune escapeOncotarget, 2014
- Tumor treating fields: a new frontier in cancer therapyAnnals of the New York Academy of Sciences, 2013
- NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modalityEuropean Journal Of Cancer, 2012
- Tumor treating fields: concept, evidence and futureExpert Opinion on Investigational Drugs, 2011
- Potential therapeutic implications of cancer stem cells in glioblastomaBiochemical Pharmacology, 2010
- Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields)BMC Medical Physics, 2009
- O6‐methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cellsJournal of Neurochemistry, 2006
- Disruption of Cancer Cell Replication by Alternating Electric FieldsCancer Research, 2004